Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05244629

Copenhagen Mesenteric Stent Study - A Randomized Trial of Stent Versus Covered Stent Treatment for Chronic Mesenteric Ischemia

Chronic mesenteric ischemia (CMI) is often caused by narrowings in the arteries providing blood to the intestines. Endovascular stent placement is considered the preferred treatment for this condition. Guidelines increasingly support the use of so called covered stents (CS) in stead of bare stents (BMS) for this use but the level of evidence for this is limited. Using CS incur additional costs for healthcare short-term but may prevent recurrence of narrowing and symptoms postoperatively benefitting patients and healthcare.

Study Objective:

To evaluate the outcomes after stenting of mesenteric arteries using BMS or CS.

Study Outcome:

Primary stent patency 1 year after placement

The trial will also evaluate complications, how often stents need to be reoperated, Quality of Life (QoL) and reasons for subjects death

Method:

This is a so called prospective, randomized controlled trial comparing CS vs. BMS. This means that one patients have agrred to treatment they will be randomly selected for treatment with either CS or BMS . The stent metal structure is identical in the two implants and the only difference is the graft covering, making this study unique.

The study will also collect blood samples for a biobank that will be used to study markers of disease and how these effect treatment outcomes.

All patients referred to the Department of Vascular Surgery due to CMI are considered for inclusion if they havechronic symptoms consistent with CMI, significant stenosis or occlusion of the superior mesenteric artery and are > 18 years Subjects not able to provide informed consent or who have non atherosclerotic cause of CMI, signs of acute loss of blood flow to the intestines cannot participate. Previous stent treatment in the superior mesenteric artery, pregnancy, allergies to contrast or stent materials are also reasons for not being included in this trial.

Side effects, risks and disadvantages for participants The risk for procedure-related complications is less than 5% and similar in both study groups. Most short-term complications are related to vascular access sites and consist of local bleeding and thrombosis. Other potential complications include impaired renal function due to contrast use, contrast allergy, arterial dissection and death.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Department of Vascular Surgery, Heart Center, Copenhagen University Hospital - Rigshospitalet

København Ø, 2100, Denmark

Location status: Recruiting

Location contact

Alexandra Brandtzæg, MD

CONTACT

[email protected]

Jonas Eiberg, Prof

SUB_INVESTIGATOR

Lars Lønn, Prof

SUB_INVESTIGATOR

Mikkel Taudorff, MD, PhD

SUB_INVESTIGATOR

Sofie Phillipsen, RN

CONTACT

[email protected]

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with symptomatic CMI of atherosclerotic or atherothrombotic etiology
  • Intended endovascular treatment
  • Symptoms consistent with CMI (pain, weight loss, diarrhea)
  • Significant ostial stenosis (>50%) of the superior mesenteric artery on CTA
  • Significant stenosis on angiography (>50% or >15mmHg pressure gradient)
  • Patients > 18 years

Exclusion criteria

  • No informed consent
  • Non atherosclerotic cause of MI
  • Acute mesenteric ischemia (AMI)
  • Signs of acute bowel ischemia, peritonitis, laparotomy, sepsis
  • Previous stent treatment in the superior mesenteric artery(ies)
  • Target artery lesions >4cm in length
  • Unable to cross lesion with guidewire
  • Non-significant stenosis angiographically
  • Pregnancy
  • Allergies to contrast media or stent materials

Treatment and study plan

BMS vs. CS

Device

Patients will be randomized to treatment with either BeSmooth (BMS, Bentley Innomed GmBh) or BeGraft (CS, Bentley Innomed Gmbh)

Primary outcomes

  1. Number of patients with open stents after 12 months

    Time frame: 12 months

    No evidence of occlusion, thrombosis or in-stent restenosis more than 30 percent

Secondary outcomes

  1. Survival

    Time frame: 5 years

    reintervention free and overall survival

  2. Quality of life accoring to SF 36 variables

    Time frame: 5 years

    SF 36

Study contacts

Contact information is provided by the study sponsor or research team.

Jonas Eiberg, MD, PhD

CONTACT

[email protected]

+45 35 45 24 08

Timothy A Resch, MD, PhD

CONTACT

[email protected]

+45 35 45 79 31 ext. 57931

Sponsors and collaborators

Lead sponsor

Rigshospitalet, Denmark

Other

Collaborators

  • University of Copenhagen

Registry information

Acronym: COMESS

Important dates

Study start
2023
Primary completion
2024
Study completion
2029
First posted
Feb 17, 2022
Registry last updated
Jun 12, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.